Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Marinus Pharmaceuticals Inc shares valued at $5,262 were sold by Pfanstiel Steven on Aug 05 ’24. At $1.13 per share, Pfanstiel Steven sold 4,657 shares. The insider’s holdings dropped to 79,773 shares worth approximately $0.14 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Shafer Christina sold 3,820 shares, netting a total of over 4,355 in proceeds. Following the sale of shares at $1.14 each, the insider now holds 67,406 shares.
Before that, MANNING MARTHA E had sold 3,621 shares from its account. In a trade valued at $4,092, the SVP, GEN. COUNSEL & CORP. SEC. traded Marinus Pharmaceuticals Inc shares for $1.13 each. Upon closing the transaction, the insider’s holdings decreased to 3,621 shares, worth approximately $0.1 million.
As published in a research note from Oppenheimer on September 23, 2024, Marinus Pharmaceuticals Inc [MRNS] has been rated up from a Perform to an Outperform and the price target has been revised to $6. Analysts at Ladenburg Thalmann downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid August. As of April 16, 2024, Robert W. Baird has decreased its “an Outperform” rating to a “Neutral” for MRNS. Earlier on April 15, 2024, RBC Capital Mkts downgraded its rating. Their new recommendation was “a Sector perform” for MRNS stock which previously was a “an Outperform”.
Analyzing MRNS Stock Performance
During the last five days, there has been a drop of approximately -2.30%. Over the course of the year, Marinus Pharmaceuticals Inc shares have dropped approximately -84.36%. Shares of the company reached a 52-week high of $11.2600 on 01/08/24 and a 52-week low of $1.0500 on 08/14/24. A 50-day SMA is recorded $1.4272, while a 200-day SMA reached $4.7167. Nevertheless, trading volume fell to 1.1 million shares from 1.33 million shares the previous day.
Support And Resistance Levels for Marinus Pharmaceuticals Inc (MRNS)
According to the 24-hour chart, there is a support level at 1.6367, which, if violated, would cause prices to drop to 1.5733. In the upper region, resistance lies at 1.7867. The next price resistance is at 1.8733. RSI (Relative Strength Index) is 57.47 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0429, which suggests the price will decrease in the coming days. Percent R is at 47.37%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
